EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A

Aernoud P Bavinck iD, Kyle Davis iD, Lisa van Engelshoven, Monique G van Lier iD, Tanja Hamacher iD, Nicole M A Blijlevens iD, Amy Shapiro iD, Saskia E M Schols iD, Waander L van Heerde iD

Haemophilia · 2025

DOI: 10.1111/hae.70191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Aernoud P Bavinck und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Radboud University Medical Centre, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Enzyre BV.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Coagulation testing in haemophilia A is limited by the scarcity of testing facilities capable of performing relevant assays. This issue incentivized the development of the EnzySystem for haemophilia A, a near‐patient testing platform aimed to measure Factor VIII activity and thrombin generation simultaneously within 1 h from 100 µL of whole blood. Involving end‐users throughout the development ensures innovations are well‐suited to meet real‐world clinical needs.

Aim

To determine EnzySystem's acceptance, envisioned use scenarios and determinants for implementation according to healthcare providers (HCPs) and persons with haemophilia A and caregivers (PwHA/C).

Methods

A single‐centre, cross‐sectional mixed methods study was performed involving two participant groups. The first involved 36 PwHA/C. The second group comprised five advanced practice providers, eight nurses, four pharmacists and five haematologists, all involved in haemophilia A care. The participants’ attitudes and preferences toward the EnzySystem for haemophilia A were assessed through questionnaires and focus groups.

Results

Acceptability was high for both groups. The platform was considered suitable for use in various scenarios, but self‐testing at home was prioritized by PwHA/C. HCPs placed equal emphasis on near‐patient testing in clinic to address issues with current test accessibility and turnaround time. For all potential use scenarios, demonstrating assay accuracy was a non‐negotiable prerequisite. The turnaround time and accessibility were identified as other key attributes by both groups.

Conclusion

The results of this study support the further development of the EnzySystem for haemophilia A and highlight barriers that should be addressed to facilitate implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHumansCross-Sectional StudiesMaleAdultFemaleSurveys and QuestionnairesMiddle AgedBlood Coagulation TestsFactor VIII

Stichwörter der Autor:innen

blood coagulation testshaemophilia Apatient preferencepoint‐of‐care testingthrombin generation assayuser‐centred design

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Department of Hematology, Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Enzyre, Nijmegen, the Netherlands.
  • Department of Pediatric Hematology, Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
  • Teledyne Healthcare, Eindhoven, the Netherlands.
  • Holland Innovative, Eindhoven, the Netherlands.
  • Hemophilia Treatment Centre Nijmegen-Eindhoven-Maastricht, Nijmegen, the Netherlands.

ORCID-Profile: Aernoud P Bavinck, Kyle Davis, Monique G van Lier, Tanja Hamacher, Nicole M A Blijlevens, Amy Shapiro, Saskia E M Schols, Waander L van Heerde

Förderung

  • Enzyre BV

Zitieren

APA

Bavinck, A. P., Davis, K., van Engelshoven, L., van Lier, M. G., Hamacher, T., Blijlevens, N. M. A., Shapiro, A., Schols, S. E. M., & van Heerde, W. L. (2025). Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A. Haemophilia. https://doi.org/10.1111/hae.70191

Vancouver

Bavinck AP, Davis K, van Engelshoven L, van Lier MG, Hamacher T, Blijlevens NMA, et al. Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A. Haemophilia. 2025. doi:10.1111/hae.70191

BibTeX
@article{Bavinck2025,
  author = {Bavinck, Aernoud P and Davis, Kyle and van Engelshoven, Lisa and van Lier, Monique G and Hamacher, Tanja and Blijlevens, Nicole M A and Shapiro, Amy and Schols, Saskia E M and van Heerde, Waander L},
  title = {Acceptability and Determinants for Implementation of the EnzySystem, a Novel Near‐Patient Testing Platform for Haemophilia A},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70191}
}
Kostenlos starten →